REPLIMUNE GROUP, INC. Increase (Decrease) in Accounts Payable
REPLIMUNE GROUP, INC. (REPL) reported Increase (Decrease) in Accounts Payable of -$2.33 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-14
- REPLIMUNE GROUP, INC. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$2.33M, a 161.99% decline year-over-year.
- REPLIMUNE GROUP, INC. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $956.00K, a 81.76% decline year-over-year.
- REPLIMUNE GROUP, INC. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$730.00K.
- REPLIMUNE GROUP, INC. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$8.93M, a 219.64% decline year-over-year.
- REPLIMUNE GROUP, INC. increase (decrease) in accounts payable for fiscal 2026 was -$4.94M, a 149.68% decline from fiscal 2025.
- REPLIMUNE GROUP, INC. increase (decrease) in accounts payable for fiscal 2025 was $9.94M.
- REPLIMUNE GROUP, INC. increase (decrease) in accounts payable for fiscal 2024 was -$2.79M, a 241.04% decline from fiscal 2023.
- REPLIMUNE GROUP, INC. increase (decrease) in accounts payable for fiscal 2023 was $1.98M, a 77.19% increase from fiscal 2022.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.33M 10-Q · filed 2026-08-14 | -$1.38M derived: sum of 2 quarters · filed 2026-08-14 | -$2.11M derived: sum of 3 quarters · filed 2026-08-14 | -$11.04M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $956.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | $226.00K derived: sum of 2 quarters · filed 2026-06-29 | -$8.70M derived: sum of 3 quarters · filed 2026-06-29 | -$4.94M 10-K · filed 2026-06-29 |
| 2025-12-31 | -$730.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-03 | -$9.66M derived: sum of 2 quarters · filed 2026-02-03 | -$5.89M 10-Q · filed 2026-02-03 | -$654.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-09-30 | -$8.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-06 | -$5.17M 10-Q · filed 2025-11-06 | $76.00K derived: sum of 3 quarters · filed 2026-08-14 | -$1.07M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $3.77M 10-Q · filed 2026-08-14 | $9.01M derived: sum of 2 quarters · filed 2026-08-14 | $7.86M derived: sum of 3 quarters · filed 2026-08-14 | $15.32M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $5.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | $4.09M derived: sum of 2 quarters · filed 2026-06-29 | $11.56M derived: sum of 3 quarters · filed 2026-06-29 | $9.94M 10-K · filed 2026-06-29 |
| 2024-12-31 | -$1.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-03 | $6.32M derived: sum of 2 quarters · filed 2026-02-03 | $4.70M 10-Q · filed 2026-02-03 | $3.41M derived: sum of 4 quarters · filed 2026-02-03 |
| 2024-09-30 | $7.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-06 | $5.85M 10-Q · filed 2025-11-06 | $4.56M derived: sum of 3 quarters · filed 2025-11-06 | $4.08M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$1.61M 10-Q · filed 2025-08-07 | -$2.90M derived: sum of 2 quarters · filed 2025-08-07 | -$3.38M derived: sum of 3 quarters · filed 2025-08-07 | -$3.59M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-22 | -$1.76M derived: sum of 2 quarters · filed 2025-05-22 | -$1.98M derived: sum of 3 quarters · filed 2025-05-22 | -$2.79M 10-K · filed 2025-05-22 |
| 2023-12-31 | -$476.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-12 | -$689.00K derived: sum of 2 quarters · filed 2025-02-12 | -$1.50M 10-Q · filed 2025-02-12 | $119.00K derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-09-30 | -$213.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-12 | -$1.03M 10-Q · filed 2024-11-12 | $595.00K derived: sum of 3 quarters · filed 2024-11-12 | $254.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$816.00K 10-Q · filed 2024-08-08 | $808.00K derived: sum of 2 quarters · filed 2024-08-08 | $467.00K derived: sum of 3 quarters · filed 2024-08-08 | $270.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-16 | $1.28M derived: sum of 2 quarters · filed 2024-05-16 | $1.09M derived: sum of 3 quarters · filed 2024-05-16 | $1.98M 10-K · filed 2024-05-16 |
| 2022-12-31 | -$341.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-08 | -$538.00K derived: sum of 2 quarters · filed 2024-02-08 | $357.00K 10-Q · filed 2024-02-08 | $282.00K derived: sum of 4 quarters · filed 2024-02-08 |
| 2022-09-30 | -$197.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-07 | $698.00K 10-Q · filed 2023-11-07 | $623.00K derived: sum of 3 quarters · filed 2023-11-07 | $1.07M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $895.00K 10-Q · filed 2023-08-03 | $820.00K derived: sum of 2 quarters · filed 2023-08-03 | $1.26M derived: sum of 3 quarters · filed 2023-08-03 | $1.95M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$75.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-05-18 | $368.00K derived: sum of 2 quarters · filed 2023-05-18 | $1.05M derived: sum of 3 quarters · filed 2023-05-18 | $1.12M 10-K · filed 2023-05-18 |
| 2021-12-31 | $443.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-09 | $1.13M derived: sum of 2 quarters · filed 2023-02-09 | $1.19M 10-Q · filed 2023-02-09 | $1.18M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-09-30 | $684.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-03 | $750.00K 10-Q · filed 2022-11-03 | $737.00K derived: sum of 3 quarters · filed 2022-11-03 | $917.00K derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $66.00K 10-Q · filed 2022-08-04 | $53.00K derived: sum of 2 quarters · filed 2022-08-04 | $233.00K derived: sum of 3 quarters · filed 2022-08-04 | -$741.00K derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-05-19 | $167.00K derived: sum of 2 quarters · filed 2022-05-19 | -$807.00K derived: sum of 3 quarters · filed 2022-05-19 | -$1.03M 10-K · filed 2022-05-19 |
| 2020-12-31 | $180.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-02-03 | -$794.00K derived: sum of 2 quarters · filed 2022-02-03 | -$1.02M 10-Q · filed 2022-02-03 | -$2.25M derived: sum of 4 quarters · filed 2022-02-03 |
| 2020-09-30 | -$974.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-11-04 | -$1.20M 10-Q · filed 2021-11-04 | -$2.43M derived: sum of 3 quarters · filed 2021-11-04 | -$4.12M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | -$224.00K 10-Q · filed 2021-08-06 | -$1.46M derived: sum of 2 quarters · filed 2021-08-06 | -$3.15M derived: sum of 3 quarters · filed 2021-08-06 | -$7.81M derived: sum of 4 quarters · filed 2021-08-06 |
| 2020-03-31 | -$1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2021-05-20 | -$2.92M derived: sum of 2 quarters · filed 2021-05-20 | -$7.58M derived: sum of 3 quarters · filed 2021-05-20 | -$3.82M 10-K · filed 2021-05-20 |
| 2019-12-31 | -$1.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-02-04 | -$6.35M derived: sum of 2 quarters · filed 2021-02-04 | -$2.58M 10-Q · filed 2021-02-04 | -$1.94M derived: sum of 4 quarters · filed 2021-02-04 |
| 2019-09-30 | -$4.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-11-05 | -$900.00K 10-Q · filed 2020-11-05 | -$259.00K derived: sum of 3 quarters · filed 2020-11-05 | -$930.00K derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $3.76M 10-Q · filed 2020-08-07 | $4.41M derived: sum of 2 quarters · filed 2020-08-07 | $3.73M derived: sum of 3 quarters · filed 2020-08-07 | $4.14M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | $641.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-03 | -$30.00K derived: sum of 2 quarters · filed 2020-06-03 | $379.00K derived: sum of 3 quarters · filed 2020-06-03 | $120.00K 10-K · filed 2020-06-03 |
| 2018-12-31 | -$671.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-02-13 | -$262.00K derived: sum of 2 quarters · filed 2020-02-13 | -$521.00K 10-Q · filed 2020-02-13 | $899.00K derived: sum of 4 quarters · filed 2020-06-03 |
| 2018-09-30 | $409.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-11-12 | $150.00K 10-Q · filed 2019-11-12 | $1.57M derived: sum of 3 quarters · filed 2020-06-03 | $1.17M derived: sum of 4 quarters · filed 2020-06-03 |
| 2018-06-30 | -$259.00K 10-Q · filed 2019-08-14 | $1.16M derived: sum of 2 quarters · filed 2020-06-03 | $760.00K derived: sum of 3 quarters · filed 2020-06-03 | $956.00K derived: sum of 4 quarters · filed 2020-06-03 |
| 2018-03-31 | $1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-03 | $1.02M derived: sum of 2 quarters · filed 2020-06-03 | $1.22M derived: sum of 3 quarters · filed 2020-06-03 | $1.60M 10-K · filed 2020-06-03 |
| 2017-12-31 | -$401.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-02-14 | -$205.00K derived: sum of 2 quarters · filed 2019-02-14 | $176.00K 10-Q · filed 2019-02-14 | |
| 2017-09-30 | $196.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-11-14 | $577.00K 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | $381.00K 10-Q · filed 2018-08-30 | |||
| 2017-03-31 | $203.00K 10-K · filed 2019-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |